The influence of pulsed high-frequency electromagnetic fields emitted from a circularly polarized antenna on the neuroendocrine system in healthy humans was investigated (900 MHz electromagnetic field, pulsed with 217 Hz, average power density 0.02 mW/cm2). Nocturnal hormone profiles of growth hormone (GH), cortisol, luteinizing hormone (LH) and melatonin were determined under polysomnographic control. An alteration in the hypothalamo-pituitary-adrenal axis activity was found with a slight, transient elevation in the cortisol serum level immediately after onset of field exposure which persisted for 1 h. For GH, LH and melatonin, no significant effects were found under exposure to the field compared to the placebo condition, regarding both total hormone production during the entire night and dynamic characteristics of the secretion pattern. Also the evaluation of the sleep EEG data revealed no significant alterations under field exposure, although there was a trend to an REM suppressive effect. The results indicate that weak high-frequency electromagnetic fields have no effects on nocturnal hormone secretion except for a slight elevation in cortisol production which is transient, pointing to an adaptation of the organism to the stimulus.

1.
Röschke J, Mann K: No short-term effects of digital mobile radio telephone on the awake human electroencephalogram. Bioelectromagnetics 1997;18:172–176.
2.
Mann K, Röschke J: Effects of pulsed high-frequency electromagnetic fields on human sleep. Neuropsychobiology 1996;33:41–47.
3.
Roberts NJ, Michaelson SM, Lu S-T: The biological effects of radiofrequency radiation: A critical review and recommendations. Int J Radiat Biol 1986;50:379–420.
4.
Polk C, Postow E: CRC Handbook of Biological Effects of Electromagnetic Fields. Boca Raton, CRC Press, 1986.
5.
Michaelson SM, Lin JC: Biological effects and Healthy Implications of Radiofrequency Radiation. New York, Plenum, 1987.
6.
Rechtschaffen A, Kales A: A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, Public Health Service, US Government Printing Office, 1968.
7.
Lotz WG, Michaelson SM: Effects of hypophysectomy and dexamethasone on rat adrenal response to microwaves. J Appl Physiol 1979;47:1284–1288.
8.
Lai H, Carino MA, Horita A, Guy AW: Corticotropin-releasing factor antagonist blocks microwave-induced decreases in high-affinity choline uptake in the rat brain. Brain Res Bull 1990;25:609–612.
9.
Lotz WG, Podgorski RP: Temperature and adrenocortical responses in rhesus monkeys exposed to microwaves. J Appl Physiol 1982;53:1565–1571.
10.
Lotz WG, Michaelson SM: Temperature and corticosterone relationships in microwave-exposed rats. J Appl Physiol 1978;44:438–445.
11.
Lu S-T, Lebda N, Pettit S, Michaelson SM: Microwave-induced temperature, corticosterone, and thyrotropin interrelationships. J Appl Physiol 1981;50:399–405.
12.
Taylor LS: The mechanisms of athermal microwave biological effects. Bioelectromagnetics 1981;2:259–267.
13.
Weaver JC, Astumian RD: The response of living cells to very weak electric fields: The thermal noise limit. Science 1990;247:459–462.
14.
Michaelson SM, Houk WM, Lebda NJA, Lu S-T, Magin RL: Biochemical and neuroendocrine aspects of exposure to microwaves. Ann NY Acad Sci 1975;247:21–44.
15.
Lebovitz RM, Johnson L, Samson WK: Effects of pulse-modulated microwave radiation and conventional heating on sperm production. J Appl Physiol 1987;62:245–252.
16.
Margonato V, Veicsteinas A, Conti R, Nicolini P, Cerretelli P: Biological effects of prolonged exposure to ELF electromagnetic fields in rats. I. 50 Hz electric fields. Bioelectromagnetics 1993;14:479–493.
17.
Reiter RJ, Richardson BA: Magnetic field effects on pineal indoleamine metabolism and possible biological consequences. FASEB J 1992;6:2283–2287.
18.
Yaga K, Reiter RJ, Manchester LC, Nieves H, Sun JH, Chen LD: Pineal sensitivity to pulsed static magnetic fields changes during the photoperiod. Brain Res Bull 1993;30:153–156.
19.
Kato M, Honma K, Shigemitsu T, Shiga Y: Effects of exposure to a circularly polarized 50-Hz magnetic field on serum and pineal melatonin levels in rats. Bioelectromagnetics 1993;14:97–106.
20.
Yellon SM: Acute 60 Hz magnetic field exposure effects on the melatonin rhythm in the pineal gland and circulation of the adult Djungarian hamster. J Pineal Res 1994;16:136–144.
21.
Reiter RJ: Melatonin suppression by static and extremely low frequency electromagnetic fields: Relationship to the reported increased incidence of cancer. Rev Environ Health 1994;10:171–186.
22.
Stevens RG, Davis S: The melatonin hypothesis: Electron power and breast cancer. Environ Health Perspect 1996;104(suppl 1):135–140.
23.
Graham C, Cook MR, Riffle DW: Human melatonin during continuous magnetic field exposure. Bioelectromagnetics 1996;18:166–171.
24.
Selmaoui B, Lambrozo J, Touitou Y: Magnetic fields and pineal function in humans: Evaluation of nocturnal acute exposure to extremely low frequency magnetic fields on serum melatonin and urinary 6-sulfatoxymelatonin circadian rhythms. Life Sci 1996;58:1539–1549.
25.
Schiffman JS, Lasch HM, Rollag MD, Flanders AE, Brainard GC, Burk DL Jr: Effect of MR imaging on the normal pineal body: Measurement of plasma melatonin levels. J Magn Reson Imaging 1994;4:7–11.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.